Lintuzumab Bi-213

N/A

Report date: 2025/09/12 17:58:31

Base Information

Drug NameLintuzumab Bi-213
Drug Alias NameBismab-AHuM195-Bi-213Monoclonal antibody M195 Bi-213 conjugateAnti-CD33 monoclonal antibody M195 Bi-213Bi213 MOAB M195 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionIonising radiation emittersMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia

Other Information

ATC CodeN/A
Related LinksN/A